UNIGENE LABORATORIES INC (UGNE) financial statements (2020 and earlier)

Company profile

Business Address 81 FULTON STREET
BOONTON, NJ 07005
State of Incorp. DE
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2012
12/31/2011
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4
Cash and cash equivalents4
Receivables0
Inventory, net of allowances, customer advances and progress billings1
Inventory1
Other undisclosed current assets1
Total current assets:6
Noncurrent Assets
Inventory, Noncurrent1
Property, plant and equipment3
Intangible assets, net (including goodwill)2
Intangible assets, net (excluding goodwill)2
Prepaid expense and other noncurrent assets0
Total noncurrent assets:6
TOTAL ASSETS:11
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities4
Accounts payable1
Accrued liabilities2
Accounts payable and other accrued liabilities1
Debt77
Deferred compensation liability1
Other undisclosed current liabilities23
Total current liabilities:104
Noncurrent Liabilities
Long-term debt and lease obligation0
Capital lease obligations0
Liabilities, other than long-term debt5
Other liabilities5
Other undisclosed noncurrent liabilities1
Total noncurrent liabilities:6
Total liabilities:110
Stockholders' equity
Stockholders' equity attributable to parent(99)
Common stock1
Additional paid in capital117
Accumulated deficit(217)
Total stockholders' equity:(99)
TOTAL LIABILITIES AND EQUITY:11

Income statement (P&L) ($ in millions)

12/31/2012
12/31/2011
Revenues9
Revenue, net6
Cost of revenue
(Cost of Goods and Services Sold)
(5)
Gross profit:5
Operating expenses(19)
Other undisclosed operating income5
Operating loss:(9)
Interest and debt expense(14)
Loss from continuing operations before equity method investments, income taxes:(23)
Loss from equity method investments(1)
Other undisclosed loss from continuing operations before income taxes(12)
Loss from continuing operations before income taxes:(36)
Income tax benefit1
Net loss:(34)
Net loss attributable to noncontrolling interest(0)
Other undisclosed net income attributable to parent0
Net loss available to common stockholders, diluted:(34)

Comprehensive Income ($ in millions)

12/31/2012
12/31/2011
Net loss:(34)
Comprehensive loss, net of tax, attributable to parent:(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: